Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary

Nordicus Partners Corp

Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.
Transaction closed November 12, 2024; Orocidin now 100% owned by Nordicus.
Orocidin is a clinical-stage biopharma developing periodontitis therapies.
Follows Nordicus' May 2024 purchase of 95% of Orocidin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.